SMMT: Four positive phase III trials and accelerated timelines position the team as a leader in oncology
น้อยกว่า 1 นาทีในการอ่าน
The session highlighted rapid progress in oncology, with four positive phase III trials for ivonescimab, strong global data consistency, and accelerated regulatory timelines. The team remains confident in its independent strategy, financial strength, and ability to outpace competitors.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr